Reviewing politics
and culture since 1913

Advertorial: written and funded by AstraZeneca
  1. Sponsored
  2. Healthcare
15 October 2026

The NHS needs a new model for cardiovascular care

Meeting its ambitions will require a shift from a fragmented, reactive model to integrated, preventative pathways

By Tom Keith-Roach

Around 33,000 people under the age of 75 die from cardiovascular disease every year in England.1 Behind that statistic lies one of the country’s largest health challenges, growing pressure on NHS services and widening inequalities.

This burden is not felt equally: people living in the most deprived communities are more likely to develop cardiovascular, kidney and metabolic (CVKM) diseases earlier, experience poorer outcomes, and spend longer out of work due to ill health. The impact extends beyond health alone, with more than 770,000 working-age adults with cardiovascular conditions currently out of work, contributing to around £1.2bn in lost productivity annually.2

The publication of the NHS Cardiovascular Disease Modern Service Framework (MSF) marks an important moment in addressing these challenges. Its ambition is clear: to reduce premature deaths from heart disease and stroke by 25 per cent over the next decade.3

The ambitions set out in the MSF demand a fundamental shift in how care is delivered across the NHS. Too much of today’s system focuses on managing disease after it develops, rather than identifying risk early, preventing progression and supporting people to manage their health proactively. The full value of innovative treatment, technology and data cannot be realised through fragmented pathways. Bringing these capabilities together through integrated, patient-centred, technology-enabled models of care would allow earlier risk identification, faster intervention and better support at a time when demand continues to grow.

Gift a New Statesman subscription for only £2

The case for integrated care

People increasingly live with multiple interconnected health challenges, and patients do not experience CVKM conditions in isolation. That reality is reflected in the scale of cardiovascular risk across the population. More than one-third of adults in England have hypertension, while almost 60 per cent of hypertension cases remain undiagnosed.4

This pattern of overlapping risk means that a person with high blood pressure is rarely managing a single diagnosis; UK health data tell us that roughly two in five adults with hypertension are also living with obesity5, hypertension are simultaneously living with obesity, while over two-thirds of those with type 2 diabetes have at least one comorbidity, the most common being hypertension, depression and coronary heart disease.6 Yet, healthcare pathways are still designed. Yet, healthcare pathways are still designed around individual diseases, with separate specialties, services and clinical teams.

The result is a disjointed system complex, for both patients and healthcare professionals. Patients are frequently required to navigate multiple appointments, providers and care plans. Opportunities to identify risk, intervene earlier and coordinate care are often missed. In a health service under significant pressure, the NHS cannot afford to continue to operate in this manner.

How CVKM changes the conversation

With this national mandate for CVKM integration now in our hands, we have an opportunity to create a connected pathway spanning prevention, diagnosis, treatment and long-term management. By bringing primary care, community pharmacy and specialist care closer together, Integrated Care Boards can reduce duplication, ease pressure on the NHS, making every patient contact count, and reducing avoidable cardiovascular events and variations in outcomes across communities.

Take risk management: traditional healthcare pathways are often activated when a person presents to the health system after having developed a condition or experienced an event. By contrast, the changing healthcare landscape could allow us to identify risk earlier and intervene before serious complications occur.

With at least 70 per cent of cardiovascular disease associated with preventable or modifiable risk factors,7 there are proactive approaches waiting to be grasped through the expanding role of pharmacists in managing health locally through health checks; the explosion of wearable technologies building individual health awareness; and the emerging capability of AI to assist in case finding across medical records.

Prevention at scale requires a new model

The current reactive approach to care is baked into the NHS. And while NHS England has articulated a 21st century ambition, will the health system have the courage to leave behind the 20th century model of care? Physical appointments, episodic interactions, and treatment once disease has already taken hold can no longer be the norm. It is simply not capable of identifying risk across entire populations, supporting continuous management of long-term conditions, or intervening consistently before serious cardiovascular events occur.

The convergence of AI, digital health and new workforce models creates a once-in-a-generation opportunity to redesign care around patients rather than institutions. With more than 39 million registered users, the NHS App has the potential to become a gateway to more personalised, preventative and connected care.8

But government, the NHS and industry must work together to ensure sufficient investment in digital infrastructure, interoperability and workforce capability – so these advances in remote monitoring, digital therapeutics, population health management, proactive case finding, and AI-enabled risk stratification can be scaled consistently, rather than remaining isolated examples of good practice.

We are not starting from scratch: innovative models already exist, such as the LUCID programme, delivered through a joint working partnership between AstraZeneca, University Hospitals Leicester, and primary care teams. This integrated primary- and secondary-care model uses virtual multidisciplinary teams to identify high-risk chronic kidney disease patients, optimise treatment, and reduce emergency admissions and long-term NHS costs.9

The challenge is embedding such innovation sustainably into everyday care at scale. Local systems need flexibility to tailor services to population needs, supported by a national framework that ensures equitable access to evidence-based care wherever patients live.

Turning ambition into action

Major transformation requires collective political and financial commitment. For AstraZeneca, this means bringing innovative medicines to the UK, working with government and NHS England to redesign care around growing demand, and partnering with local health leaders to transform pathways.

This agenda can also drive growth: adopting UK-developed medicines, digital tools and health technologies can improve outcomes, create skilled jobs and strengthen local economies.Our goal is to turn the MSF’s ambition into reality through partnership. By combining the NHS’s reach and clinical expertise with industry’s scientific, technological and delivery capabilities, the triple helix of government, NHS and industry can build a future-ready model of care that protects the nation’s health.

***

  1. Department of Health and Social Care and NHS England. Cardiovascular disease (CVD) modern service framework (MSF): a cardiovascular-kidney-metabolic approach – the strategic vision and delivery model. Published 7 July 2026. Accessed October 2026 ↩︎
  2. Department of Health and Social Care and NHS England. Cardiovascular disease (CVD) modern service framework (MSF): a cardiovascular-kidney-metabolic approach – the strategic vision and delivery model. Published 7 July 2026. Accessed October 2026 ↩︎
  3. Department of Health and Social Care and NHS England. Cardiovascular disease (CVD) modern service framework (MSF): a cardiovascular-kidney-metabolic approach – the strategic vision and delivery model. Published 7 July 2026. Accessed October 2026 ↩︎
  4. Liu W, Collister J, Littlejohns T, Turnbull IJ, Clarke R, Hunter DJ, et al. Hypertension prevalence, detection, treatment and control among 1.4 million adults in England: a cross-sectional analysis from the Our Future Health study in 2022–2025. BMJ Public Health. 2026;4:e004815. Available at: Accessed October 2026 ↩︎
  5. Tapela N, Collister J, Clifton L, Turnbull I, Rahimi K, Hunter DJ. Prevalence and determinants of hypertension control among almost 100 000 treated adults in the UK. Open Heart. 2021 Feb;8(1):e001461. doi: 10.1136/openhrt-2020-001461. PMID: 33707223; PMCID: PMC7957140. Accessed October 2026 ↩︎
  6. Morris A, Bright C, Cocks M, et al. Recommendations from Diabetes UK’s 2022 diabetes and physical activity workshop. Diabet Med. 2023; 40:e15169. doi:10.1111/dme.15169. Accessed October 2026 ↩︎
  7. Department of Health and Social Care and NHS England. Cardiovascular disease (CVD) modern service framework (MSF): a cardiovascular-kidney-metabolic approach – the strategic vision and delivery model. Published 7 July 2026. Accessed October 2026 ↩︎
  8. NHS England. Record numbers using NHS App to manage health. Published December 2025. Accessed October 2026 ↩︎
  9. AstraZeneca UK. Purpose-led Partnerships: Transforming Healthcare and Advancing Practice Change. June 2025. Accessed October 2026 ↩︎

Topics in this article :